title: Stress response of glioblastoma cells mediated by miR-17-5p targeting PTEN and the passenger strand miR-17-3p targeting MDM2.
abstract: Tumor development not only destroys the homeostasis of local tissues but also the whole body, and thus the tumor cells have to face the body's defense system, a shortage of nutrition and oxygen, and chemotherapeutic drug treatment. In response to these stresses, tumor cells often alter gene expression and microRNA levels to facilitate survival. We have demonstrated that glioblastoma cells deprived of nutrition or treated with chemotherapeutics drugs expressed increased levels of miR-17. Ectopic transfection of miR-17 prolonged glioblastoma cell survival when the cells were deprived with nutrition or treated with chemotherapeutic drugs. Expression of miR-17 also promoted cell motility, invasion, and tube-like structure formation. We found that these phenotypes were the results of miR-17 targeting PTEN. As a consequence, HIF1α and VEGF were up-regulated. Ectopic expression of miR-17 was found to facilitate enrichment of stem-like tumor cells, since the cells became drug-resistant, showed increased capacity to form colonies and neurospheres, and expressed higher levels of CD133, a phenotype similar to ectopic expression of HIF1α. To further confirm the phenotypic property of stem cells, we demonstrated that glioblastoma cells transfected with miR-17 proliferated slower in different nutritional conditions by facilitating more cells staying in the G1 phase than the control cells. Finally, we demonstrated that miR-17 could repress MDM2 levels, resulting in decreased cell proliferation and drug-resistance. Our results added a new layer of functional mechanism for the well-studied miRNA miR-17.
authors: Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto.
authors: Haoran
authors: H
authors: Li
authors: Burton B
authors: BB
authors: Yang
mesh_terms: D000071916:AC133 Antigen; D015703:Antigens, CD / Q000378:metabolism; D000970:Antineoplastic Agents / Q000494:pharmacology; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D015971:Gene Expression Regulation, Enzymologic; D015972:Gene Expression Regulation, Neoplastic; D005838:Genotype; D005909:Glioblastoma / Q000098:blood supply / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D006023:Glycoproteins / Q000378:metabolism; D006801:Humans; D051795:Hypoxia-Inducible Factor 1, alpha Subunit / Q000235:genetics / Q000378:metabolism; D035683:MicroRNAs / Q000378:metabolism*; D009361:Neoplasm Invasiveness; D014411:Neoplastic Stem Cells / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D009389:Neovascularization, Pathologic; D051059:PTEN Phosphohydrolase / Q000235:genetics* / Q000378:metabolism; D010455:Peptides / Q000378:metabolism; D010641:Phenotype; D051736:Proto-Oncogene Proteins c-mdm2 / Q000235:genetics / Q000378:metabolism*; D013312:Stress, Physiological / Q000235:genetics*; D013997:Time Factors; D014162:Transfection; D015854:Up-Regulation; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics / Q000378:metabolism
chemical_list: D000071916:AC133 Antigen; D015703:Antigens, CD; D000970:Antineoplastic Agents; D006023:Glycoproteins; C497442:HIF1A protein, human; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; C524941:MIRN17 microRNA, human; D035683:MicroRNAs; C000606023:PROM1 protein, human; D010455:Peptides; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; C497206:MDM2 protein, human; D051736:Proto-Oncogene Proteins c-mdm2; D051059:PTEN Phosphohydrolase; C494929:PTEN protein, human
references: J Proteome Res. 2010 Jan;9(1):179-91
references: 19894763
references: Cell Cycle. 2011 Jul 1;10(13):2045-6
references: 21623159
references: Neuro Oncol. 2010 Mar;12(3):233-42
references: 20167811
references: Oncotarget. 2011 Dec;2(12):1265-78
references: 22246208
references: Cancer Res. 2007 Feb 1;67(3):976-83
references: 17283129
references: Genes Dev. 2000 Jan 1;14(1):34-44
references: 10640274
references: Cell Cycle. 2009 Nov 1;8(21):3462-8
references: 19823042
references: Nature. 2012 Aug 23;488(7412):522-6
references: 22854781
references: PLoS One. 2010 Jun 30;5(6):e11387
references: 20613982
references: Cell Cycle. 2012 Mar 15;11(6):1235-46
references: 22356767
references: PLoS One. 2009 Oct 21;4(10):e7535
references: 19844573
references: Mol Cell Biol. 2006 Nov;26(21):8191-201
references: 16940181
references: Cell. 2007 Dec 14;131(6):1109-23
references: 18083101
references: Cell Cycle. 2011 Sep 1;10(17):2827-8
references: 21869596
references: Cell Cycle. 2009 Dec;8(23):3866-73
references: 19887902
references: Neuroscience. 2011 Dec 1;197:37-47
references: 21946010
references: Cell Cycle. 2011 Oct 1;10(19):3219-20
references: 21937877
references: Oncotarget. 2012 Nov;3(11):1439-54
references: 23183822
references: Clin Pharmacol Ther. 2013 Jan;93(1):98-104
references: 23212103
references: Matrix Biol. 2013 Mar 11;32(2):74-85
references: 23159731
references: J Clin Invest. 2010 Nov;120(11):3815-7
references: 20972325
references: Cell Cycle. 2012 Aug 15;11(16):3097-108
references: 22871741
references: Cell. 2010 Jan 8;140(1):111-22
references: 20085706
references: J Neurooncol. 2011 May;103(1):43-58
references: 20835751
references: Oncotarget. 2012 Jul;3(7):723-34
references: 22869051
references: J Cell Sci. 2011 Aug 15;124(Pt 16):2826-36
references: 21807947
references: Oncotarget. 2011 Mar;2(3):259-64
references: 21436470
references: Oncotarget. 2010 Jul;1(3):224-7
references: 20936047
references: Proc Natl Acad Sci U S A. 2012 Nov 27;109(48):19864-9
references: 23150554
references: Cell Cycle. 2011 Apr 1;10(7):1121-31
references: 21368580
references: Cell. 2012 Mar 16;148(6):1172-87
references: 22424228
references: Nature. 2010 Dec 9;468(7325):829-33
references: 21102433
references: Brain Pathol. 2010 May;20(3):539-50
references: 19775293
references: Oncogene. 2011 Oct 13;30(41):4231-42
references: 21532615
references: Cancer Res. 2006 Nov 15;66(22):10843-8
references: 17108120
references: Cell. 2005 Jul 15;122(1):6-7
references: 16009126
references: Nature. 2010 Dec 9;468(7325):824-8
references: 21102434
references: World J Gastroenterol. 2012 Oct 7;18(37):5188-96
references: 23066312
references: Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20350-5
references: 18077375
references: Oncotarget. 2010 Dec;1(8):710-20
references: 21321380
references: Cell Cycle. 2008 Dec;7(23):3731-6
references: 19029807
references: Cell. 2007 Jun 15;129(6):1141-51
references: 17524464
references: Nature. 2012 Feb 15;482(7385):347-55
references: 22337054
references: Nucleic Acids Res. 2011 Apr;39(8):3026-41
references: 21149267
references: Oncogene. 2011 Aug 4;30(31):3454-67
references: 21383690
references: Oncotarget. 2012 Nov;3(11):1370-85
references: 23211491
references: Neuro Oncol. 2005 Apr;7(2):134-53
references: 15831232
references: J Cell Sci. 2012 Apr 15;125(Pt 8):2075-85
references: 22637644
references: Nat Cell Biol. 2009 Aug;11(8):1031-8
references: 19633662
references: Oncogene. 2010 Jun 10;29(23):3411-22
references: 20305691
references: Protein Cell. 2010 Jul;1(7):638-55
references: 21203936
references: Nat Med. 2011 Nov 20;17(12):1627-35
references: 22101765
references: Histol Histopathol. 2012 Oct;27(10):1263-70
references: 22936445
references: Cell. 2005 Nov 18;123(4):607-20
references: 16271386
references: PLoS One. 2008 Jun 18;3(6):e2420
references: 18560585
references: Oncotarget. 2011 Mar;2(3):265-70
references: 21454924
references: Cell Cycle. 2011 Mar 1;10(5):751-9
references: 21311220
references: Breast Cancer Res. 2011 Jan 11;13(1):R3
references: 21223569
references: Oncotarget. 2011 Jan-Feb;2(1-2):29-42
references: 21378409
references: Cell Cycle. 2011 Sep 1;10(17):2845-9
references: 21857153
references: Adv Cancer Res. 2009;102:19-65
references: 19595306
references: Cancer Res. 2007 May 15;67(10):4742-50
references: 17510402
references: Cell Cycle. 2011 Oct 1;10(19):3211-2
references: 21941082
references: Oncogene. 2011 Feb 17;30(7):806-21
references: 20956944
references: Prostate. 2009 Feb 15;69(3):263-75
references: 19016246
references: Cancer Res. 2011 Sep 15;71(18):5950-4
references: 21917736
references: Nat Genet. 2004 Oct;36(10):1079-83
references: 15361871
references: PLoS One. 2010 Oct 25;5(10):e13599
references: 21049042
references: Cell. 2008 Apr 18;133(2):217-22
references: 18423194
references: Cell Cycle. 2012 Dec 1;11(23):4352-65
references: 23111389